0.54
-0.0279(-4.89%)
Currency In USD
| Previous Close | 0.57 |
| Open | 0.56 |
| Day High | 0.58 |
| Day Low | 0.53 |
| 52-Week High | 6 |
| 52-Week Low | 0.45 |
| Volume | 250,740 |
| Average Volume | 182,468 |
| Market Cap | 1.7M |
| PE | -0.68 |
| EPS | -0.78 |
| Moving Average 50 Days | 0.92 |
| Moving Average 200 Days | 1.68 |
| Change | -0.04 |
If you invested $1000 in 60 Degrees Pharmaceuticals, Inc. (SXTP) since IPO date, it would be worth $1.93 as of January 14, 2026 at a share price of $0.543. Whereas If you bought $1000 worth of 60 Degrees Pharmaceuticals, Inc. (SXTP) shares 2 years ago, it would be worth $9.1 as of January 14, 2026 at a share price of $0.543.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State
GlobeNewswire Inc.
Dec 29, 2025 1:01 PM GMT
Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA® (tafenoquine) for treatment of chronic babesiosisData support theory among specialists that Babesia infection may prolong recovery times in patients wi
60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026
GlobeNewswire Inc.
Dec 11, 2025 1:01 PM GMT
6-month commercial pilot demonstrated increasing demand among prescribersExpansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaignAdditional clinical sites in ongoing babesiosis treat
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine
GlobeNewswire Inc.
Nov 21, 2025 1:01 PM GMT
90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatmentStudy will run approximately 12 months and enroll up to 100 patientsInternal estimates of the unmet medical need are between 4,400